Open AccessST2 in heart failure with reduced and mid-range ejection fraction: clinical and instrumental relationships and prognostic value
Author(s) -
Natalya V. Kompanets,
Olesya Yu. Aidumova,
Yu. V. Shchukin
Publication year - 2021
Publication title -
nauka i innovacii v medicine
Language(s) - English
Resource type - Journals
eISSN - 2618-754X
pISSN - 2500-1388
DOI - 10.35693/2500-1388-2021-6-4-55-58
Subject(s) - ejection fraction , cardiology , medicine , heart failure , myocardial infarction , etiology , odds ratio , diastole , stenosis , blood pressure
Objectives to determine the clinical and instrumental relationships and prognostic value of sST2 in chronic heart failure with reduced and mid-range ejection fraction of ischemic etiology.
Material and methods. The study included examination of 64 patients with heart failure with left ventricular ejection fraction 50% and myocardial infarction in medical history; mean age 55.7 8.7 years.
Results. Higher concentrations sST2 was determined with an increased end-diastolic volume, left ventricular aneurysm, left main coronary artery stenosis, glomerular filtration rate 90 ml/min/1.73 m2 (p 0.05 for all ). The study confirmed a high predictive significance of increased levels sST2 (p = 0.001); the area under the curve was 0.772; the odds ratio for an adverse outcome with sST2 35 ng/ml was 3.93.
Conclusion. sST2 is a predictor of adverse outcome during the first year of follow-up in patients with heart failure with reduced and mid-range ejection fraction of ischemic etiology.